This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.
Do Options Traders Know Something About Inovio (INO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio
by Zacks Equity Research
QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Is a Surprise Coming for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.
Company News for Dec 28, 2020
by Zacks Equity Research
Companies In The News Are: BUD, APO, INO, GOOGL, INTC, CLDR
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
Are Options Traders Betting on a Big Move in Inovio Pharmaceuticals (INO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
by Indrajit Bandyopadhyay
In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
Is the Options Market Predicting a Spike in Inovio (INO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
Why Inovio Pharmaceuticals Skyrocketed on Tuesday
by Madeleine Johnson
Shares of coronavirus stock Inovio Pharmaceuticals (INO) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.
Company News for Sep 10, 2020
by Zacks Equity Research
Companies in the news are: SCWX, ITCI, AMYT, INO
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Why Inovio Pharmaceuticals Plunged 20% Today
by Madeleine Johnson
Shares of biotech company Inovio Pharmaceuticals (INO) fell sharply on Tuesday after announcing updates to its Covid-19 vaccine candidate, INO-4800.
Moderna Collaborates With Catalent for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
Futures Reverse Higher Overnight
by Jeremy Mullin
Negative headlines can???t shake the bulls
Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why
by Zacks Equity Research
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
5 High Beta ETFs That Are in High Momentum
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.